HIPSlibrary screening

CALIBR ReFRAMElibrary screening

Japanese Consortiumlibrary screening: Eisai, Takeda & Daiichi Sankyo

Access strategyIncluding manufacturing

development

Sitafloxacin

Approved in USAfor CABP

Approved in USA, withlimited Neo & Paeds label

Paediatric cefepime-taniborbactam(NCE) Venatorx Pharmaceuticals

Approved in Asiafor CABP/cUTIs

Potential candidate B(NCE)

Potential candidate C(NCE)

Fosfomycin

Flomoxef

SERIOUS BACTERIAL INFECTIONS

NEONATALSEPSIS

PAEDIATRIC

CHIL

DRE

N Amikacin

SEXUALLY TRANSMITTED

INFECTIONS

Potential candidate A(NCE or repurposed)

Zoliflodacin (NCE)Entasis Therapeutics Inc.

Polymyxin B

Cefepime-taniborbactam(NCE)

VenatorxPharmaceuticals1

Treatment options serious bacterial infections

paediatric and neonates

DISCOVERY TRANSLATIONAL DEVELOPMENT IMPLEMENTATION

Pre-clinical Phase 1 Phase 2a PoC Phase 2b/3 Registration Access-Stewardship

Approved in Asia:Neo & Paeds data

Approved globally:Neo & Paeds data

Treatment regimen neonatal sepsis

Approved in EU, withlimited Neo & Paeds label

PROGRAMMES

GARDP PIPELINE

1 Development of cefepime-taniborbactam is sponsored by Venatorx Pharmaceuticals and has been funded in whole or in part with federal funds from NIAID/NIH/HHS and BARDA/ASPR/HHS in the United States and The Wellcome Trust in the United Kingdom

April 2020